Treatment of Ulcers In Scleroderma PDF Print E-mail
Thursday, 25 August 2011 22:11
Digital ulcers may develop in Scleroderma patients. Most systemic sclerosis patients will have digital ulcers at some point. In some, ulcers are persistent. Sometimes they progress to gangrene and amputation.

These Scleroderma ulcers are difficult to treat because of vascular disease in Scleroderma. In general, the treatment of scleroderma ulcers should be multi-faceted. It should include non-pharmacological and pharmacological measures. Antibiotics should be used judiciously. Surgical evacuation of pus is sometimes needed. Sometimes debridement is necessary.

Prevention of Scleroderma Ulcers
Ulcer prevention in patients with scleroderma is important. Once ulcers develop, treatment is difficult. Ulcer prevention involves thermal protection and prevention of trauma. Thermal protection is achieved by gloves, socks and hand and feet active warming. Cold exposure should be avoided. Good skin care is essential.

Bosentan has been shown to prevent new digital ulcer formation in patients with systemic sclerosis. It did not promote ulcer healing, though.

Mechanical treatment of scleroderma ulcers
Non-healing ulcers have been treated with Aircast™ arterial compression. These have been shown to improve ulcer healing in persons with critical limb ischemia and upper extremity ulcers.

Pharmacological treatment of scleroderma ulcers
Most patients with systemic sclerosis who develop severe Raynaud’s phenomena or digital ulcers will be offered pharmacological treatment. There are several drugs that have been suggested for the treatment of scleroderma ulcers:
  • Calcium channel antagonists – Di-hydropiridine type calcium channel antagonists have robust data in helping patients with digital ischemia. Medication such as nifedipine should be offered to these patients.
  • Bosentan – Bosentan is an endothelin receptor antagonist. It is well known from the field of pulmonary hypertension. It is recommended in the prevention of digital ulcers, as described above.
  • Sildanefil – Sildanefil is a phosphodiesterase 5 inhibitor. It has vasodilating effects. It is given in sexual dysfunction and pulmonary hypertension. Data for Sildanefil in the treatment of scleroderma ulcers is out there but is less robust. There is also data about Sildanefil and Raynaud’s phenomenon.
  • Iloprost – Iloprost is a vasodilating prostaglandin. It is administered intravenously. It has been shown to reduce the severity of ischemic attacks in patients with systemic sclerosis.

Surgical treatment of scleroderma ulcers
Surgical treatment of scleroderma ulcers involves sympathectomy. Sympathectomy can be thoracic or local, in the hand. Sympathectomy in the hand is called periarterial. It is probably useful for digital ulcers and Raynaud’s phenomena from connective tissue disease. It is probably not useful for ulcers secondary to atherosclerosis. Hand sympathectomy can be done with surgery or with botox injection.

For more on digital ulcers, read one of our previous articles here.

Source: Weinberg, I (2011), "Scleroderma Ulcers Treatment", Vascular Medicine; original article can be viewed here.


 
More articles :

» Researchers Gain Deeper Insights Into Causes And New Treatment Strategies For Scleroderma

Using mice, lab-grown cells and clues from a related disorder, Johns Hopkins researchers have greatly increased understanding of the causes of , showing that a critical culprit is a defect in the way certain cells communicate with their structural...

» Researchers Identify Core Genetic Switch As A Viable Target For New Scleroderma Treatments

Scleroderma is a rare, autoimmune disease. Often fatal, it causes the fibrosis or thickening of the connective tissue which support the skin and other vital organs within the body, through the overproduction of . The disease currently lacks a cure...

» A Checklist For Scleroderma Patients

The has published a quite useful checklist of items, which has been found useful to patients. They have noted that the list is by no means comprehensive, but is intended as a guideline to assist Scleroderma patients, and was developed by patients...

» Liver Autoantibodies in Patients with Scleroderma

Thelma L. Skare & Renato M. Nisihara & Osvaldo Haider & Pedro M. Azevedo & Shirley R. R. UtiyamaReceived: 5 January 2010 / Revised: 13 August 2010 / Accepted: 26 September 2010# Clinical Rheumatology 2010Association between...

» Palliative Care

Palliative care (pronounced pal-lee-uh-tiv) is the medical specialty focused on improving the quality of life of people facing serious illness. Emphasis is placed on pain and symptom management, communication and coordinated care. Palliative care is...

» Lower Extremity Ulcers in Systemic Sclerosis: Features and Response to Therapy

Victoria K. Shanmugam, MBBS, MRCP; Patricia Price, PhD; Christopher E. Attinger, MD; Virginia D. Steen, MD Non-digital lower extremity ulcers are a difficult to treat complication of scleroderma that is often refractory to therapy. They are a...